The vascular disrupting agent STA-9584 exhibits potent antitumor activity by selectively targeting microvasculature at both the center and periphery of tumors

Journal of Pharmacology and Experimental Therapeutics

Volumn 343, Issue 2, 2012, Pages 529-538

  Foley, Kevin P ^a   Zhou, Dan ^a   Borella, Chris ^a   Wu, Yaming ^a   Zhang, Mei ^a   Jiang, Jun ^a   Li, Hao ^a   Sang, Jim ^a   Korbut, Tim ^a   Ye, Josephine ^a   Zhang, Xuemei ^a   Barsoum, James ^a   Sonderfan, Andrew J ^a  

^a Synta Pharmaceuticals Corp   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; COMBRETASTATIN A4 PHOSPHATE; STA 9122; STA 9584; TUBULIN; UNCLASSIFIED DRUG; VASCULAR TARGETING AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST TUMOR; CANCER INHIBITION; CARDIOTOXICITY; CARDIOVASCULAR EFFECT; CELL VIABILITY; CONTROLLED STUDY; DOG; DRUG CYTOTOXICITY; DRUG DOSE ESCALATION; DRUG DOSE TITRATION; DRUG POTENCY; DRUG SAFETY; DRUG STRUCTURE; DRUG TARGETING; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; ISOLATED HEART; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE TUMOR; STRUCTURE ANALYSIS; TUMOR VASCULARIZATION; TUMOR XENOGRAFT; ULTRASOUND;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BIBENZYLS; CELL SURVIVAL; DOGS; FEMALE; HEART; HEMODYNAMICS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; ISOXAZOLES; MALE; MICE; MICE, INBRED BALB C; MICE, SCID; MICROCIRCULATION; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PHENYLALANINE; RABBITS; REGIONAL BLOOD FLOW; TUBULIN MODULATORS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84867619210     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.112.196873     Document Type: Article

References (39)

1. Beerepoot LV, Radema SA, Witteveen EO, Thomas T, Wheeler C, Kempin S, and Voest EE (2006) Phase I clinical evaluation of weekly administration of the novel vascular-targeting agent, ZD6126, in patients with solid tumors. J Clin Oncol 24:1491-1498. (Pubitemid 46638769)
2. Burns CJ, Fantino E, Phillips ID, Su S, Harte MF, Bukczynska PE, Frazzetto M, Joffe M, Kruszelnicki I, Wang B, et al. (2009) CYT997: a novel orally active tubulin polymerization inhibitor with potent cytotoxic and vascular disrupting activity in vitro and in vivo. Mol Cancer Ther 8:3036-3045.
3. Cooney MM, Radivoyevitch T, Dowlati A, Overmoyer B, Levitan N, Robertson K, Levine SL, DeCaro K, Buchter C, Taylor A, et al. (2004) Cardiovascular safety profile of combretastatin a4 phosphate in a single-dose phase I study in patients with advanced cancer. Clin Cancer Res 10:96-100. (Pubitemid 38114167)
4. Dowlati A, Robertson K, Cooney M, Petros WP, Stratford M, Jesberger J, Rafie N, Overmoyer B, Makkar V, Stambler B, et al. (2002) A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin a-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer. Cancer Res 62:3408-3416. (Pubitemid 34651387)
5. Dvorak HF, Nagy JA, Dvorak JT, and Dvorak AM (1988) Identification and characterization of the blood vessels of solid tumors that are leaky to circulating macromolecules. Am J Pathol 133:95-109.
6. Eberhard A, Kahlert S, Goede V, Hemmerlein B, Plate KH, and Augustin HG (2000) Heterogeneity of angiogenesis and blood vessel maturation in human tumors: implications for antiangiogenic tumor therapies. Cancer Res 60:1388-1393. (Pubitemid 30152012)
7. Eichholz A, Merchant S, and Gaya AM (2010) Anti-angiogenesis therapies: their potential in cancer management. Onco Targets Ther 3:69-82.
8. Folkes LK, Christlieb M, Madej E, Stratford MR, and Wardman P (2007) Oxidative metabolism of combretastatin A-1 produces quinone intermediates with the potential to bind to nucleophiles and to enhance oxidative stress via free radicals. Chem Res Toxicol 20:1885-1894.
9. Gaya AM and Rustin GJ (2005) Vascular disrupting agents: a new class of drug in cancer therapy. Clin Oncol (R Coll Radiol) 17:277-290. (Pubitemid 40718658)
10. Grothey A and Galanis E (2009) Targeting angiogenesis: progress with anti-VEGF treatment with large molecules. Nat Rev Clin Oncol 6:507-518.
11. Hashizume H, Baluk P, Morikawa S, McLean JW, Thurston G, Roberge S, Jain RK, and McDonald DM (2000) Openings between defective endothelial cells explain tumor vessel leakiness. Am J Pathol 156:1363-1380. (Pubitemid 30660013)
12. Hida T, Tamiya M, Nishio M, Yamamoto N, Hirashima T, Horai T, Tanii H, Shi MM, Kobayashi K, and Horio Y (2011) Phase I study of intravenous ASA404 (vadimezan) administered in combination with paclitaxel and carboplatin in Japanese patients with non-small cell lung cancer. Cancer Sci 102:845-851.
13. Hill SA, Chaplin DJ, Lewis G, and Tozer GM (2002a) Schedule dependence of combretastatin A4 phosphate in transplanted and spontaneous tumour models. Int J Cancer 102:70-74.
14. Hill SA, Toze GM, Pettit GR, and Chaplin DJ (2002b) Preclinical evaluation of the antitumour activity of the novel vascular targeting agent Oxi 4503. Anticancer Res 22:1453-1458. (Pubitemid 34839149)
15. Holwell SE, Cooper PA, Grosios K, Lippert JW 3rd, Pettit GR, Shnyder SD, and Bibby MC (2002) Combretastatin A-1 phosphate a novel tubulin-binding agent with in vivo anti vascular effects in experimental tumours. Anticancer Res 22:707-711. (Pubitemid 34475218)
16. Hua J, Sheng Y, Pinney KG, Garner CM, Kane RR, Prezioso JA, Pettit GR, Chaplin DJ, and Edvardsen K (2003) Oxi4503, a novel vascular targeting agent: effects on blood flow and antitumor activity in comparison to combretastatin A-4 phosphate. Anticancer Res 23:1433-1440. (Pubitemid 36754111)
17. Institute of Laboratory Animal Resources (1996) Guide for the Care and Use of Laboratory Animals 7th ed. Institute of Laboratory Animal Resources, Commission on Life Sciences, National Research Council, Washington, DC.
18. Kanthou C and Tozer GM (2009) Microtubule depolymerizing vascular disrupting agents: novel therapeutic agents for oncology and other pathologies. Int J Exp Pathol 90:284-294.
19. Lara PN Jr, Douillard JY, Nakagawa K, von Pawel J, McKeage MJ, Albert I, Losonczy G, Reck M, Heo DS, Fan X, et al. (2011) Randomized phase III placebo-controlled trial of carboplatin and paclitaxel with or without the vascular disrupting agent vadimezan (ASA404) in advanced non-small-cell lung cancer. J Clin Oncol 29:2965-2971.
20. Lorusso PM, Boerner SA, and Hunsberger S (2011) Clinical development of vascular disrupting agents: what lessons can we learn from ASA404? J Clin Oncol 29:2952-2955.
21. LoRusso PM, Gadgeel SM, Wozniak A, Barge AJ, Jones HK, DelProposto ZS, DeLuca PA, Evelhoch JL, Boerner SA, and Wheeler C (2008) Phase I clinical evaluation of ZD6126, a novel vascular-targeting agent, in patients with solid tumors. Invest New Drugs 26:159-167.
22. McKeage MJ and Baguley BC (2010) Disrupting established tumor blood vessels: an emerging therapeutic strategy for cancer. Cancer 116:1859-1871.
23. McKeage MJ, Reck M, Jameson MB, Rosenthal MA, Gibbs D, Mainwaring PN, Freitag L, Sullivan R, and Von Pawel J (2009) Phase II study of ASA404 (vadimezan, 5,6-dimethylxanthenone-4-acetic acid/DMXAA) 1800mg/m(2) combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer. Lung Cancer 65:192-197.
24. McKeage MJ, Von Pawel J, Reck M, Jameson MB, Rosenthal MA, Sullivan R, Gibbs D, Mainwaring PN, Serke M, Lafitte JJ, et al. (2008) Randomised phase II study of ASA404 combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer. Br J Cancer 99:2006-2012.
25. Mita MM, Spear MA, Yee LK, Mita AC, Heath EI, Papadopoulos KP, Federico KC, Reich SD, Romero O, Malburg L, et al. (2010) Phase 1 first-in-human trial of the vascular disrupting agent plinabulin (NPI-2358) in patients with solid tumors or lymphomas. Clin Cancer Res 16:5892-5899.
26. Patterson DM, Zweifel M, Middleton MR, Price PM, Folkes LK, Stratford MR, Ross P, Halford S, Peters J, Balkissoon J, et al. (2012) Phase I clinical and pharmacokinetic evaluation of the vascular disrupting agent OXi4503 in patients with advanced solid tumors. Clin Cancer Res 18:1415-1425.
27. Pettit GR, Singh SB, and Cragg GM (1985) Synthesis of natural (-)-combretastatin. J Org Chem 50:3404-3406. (Pubitemid 15226019)
28. Proia DA, Foley KP, Korbut T, Sang J, Smith D, Bates RC, Liu Y, Rosenberg AF, Zhou D, Koya K, et al. (2011) Multifaceted intervention by the Hsp90 inhibitor ganetespib (STA-9090) in cancer cells with activated JAK/STAT signaling. PLoS One 6:e18552.
29. Rice L, Pampo C, Lepler S, Rojiani AM, and Siemann DW (2011) Support of a free radical mechanism for enhanced antitumor efficacy of the microtubule disruptor OXi4503. Microvasc Res 81:44-51.
30. Rustin GJ, Galbraith SM, Anderson H, Stratford M, Folkes LK, Sena L, Gumbrell L, and Price PM (2003) Phase I clinical trial of weekly combretastatin A4 phosphate: clinical and pharmacokinetic results. J Clin Oncol 21:2815-2822. (Pubitemid 46621828)
31. Rustin GJ, Shreeves G, Nathan PD, Gaya A, Ganesan TS, Wang D, Boxall J, Poupard L, Chaplin DJ, Stratford MR, et al. (2010) A Phase Ib trial of CA4P (combretastatin A-4 phosphate), carboplatin, and paclitaxel in patients with advanced cancer. Br J Cancer 102:1355-1360.
32. Shi W and Siemann DW (2005) Preclinical studies of the novel vascular disrupting agent MN-029. Anticancer Res 25:3899-3904. (Pubitemid 41665162)
33. Siemann DW (2011) The unique characteristics of tumor vasculature and preclinical evidence for its selective disruption by tumor-vascular disrupting agents. Cancer Treat Rev 37:63-74.
34. Subbiah IM, Lenihan DJ, and Tsimberidou AM (2011) Cardiovascular toxicity profiles of vascular-disrupting agents. Oncologist 16:1120-1130.
35. Thorpe PE (2004) Vascular targeting agents as cancer therapeutics. Clin Cancer Res 10:415-427.
36. Tozer GM, Kanthou C, and Baguley BC (2005) Disrupting tumour blood vessels. Nat Rev Cancer 5:423-435. (Pubitemid 40791485)
37. Van de Water A, Verheyen J, Xhonneux R, and Reneman RS (1989) An improved method to correct the QT interval of the electrocardiogram for changes in heart rate. J Pharmacol Methods 22:207-217. (Pubitemid 19275446)
38. van Heeckeren WJ, Bhakta S, Ortiz J, Duerk J, Cooney MM, Dowlati A, McCrae K, and Remick SC (2006) Promise of new vascular-disrupting agents balanced with cardiac toxicity: is it time for oncologists to get to know their cardiologists? J Clin Oncol 24:1485-1488. (Pubitemid 46638767)
39. van Heeckeren WJ, Sanborn SL, Narayan A, Cooney MM, McCrae KR, Schmaier AH, and Remick SC (2007) Complications from vascular disrupting agents and angiogenesis inhibitors: aberrant control of hemostasis and thrombosis. Curr Opin Hematol 14:468-480. (Pubitemid 47457636)